MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 49, 2010, Pages 21098-21103

  Valeri, Nicola ^a,b   Gasparini, Pierluigi ^a   Braconi, Chiara ^a   Paone, Alessio ^a   Lovat, Francesca ^a   Fabbri, Muller ^a,c   Sumani, Khlea M ^a   Alder, Hansjuerg ^a   Amadori, Dino ^c   Patel, Tushar ^a   Nuovo, Gerard J ^a   Fishel, Richard ^a   Croce, Carlo M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Colon cancer; DNA repair; Non coding RNA

Indexed keywords

FLUOROURACIL; MICRORNA 21; PROTEIN MSH2; PROTEIN MSH6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

BASE PAIR MISMATCH; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTS HOMOLOG 2 PROTEIN;

EID: 78650500590     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015541107     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338.
3. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704-714.
4. Volinia S, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261.
5. Ng EK, et al. (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 58: 1375-1381.
6. Link A, et al. (2010) Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 19:1766-1774.
7. Schetter AJ, et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436.
8. Fishel R (2001) The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: Revising the mutator hypothesis. Cancer Res 61:7369-7374.
9. Marsischky GT, Filosi N, Kane MF, Kolodner R (1996) Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 10: 407-420.
10. Ribic CM, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257.
11. Meyers M, et al. (2005) DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280:5516-5526.
12. Hewish M, et al. (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment Nat. Rev. Clin Oncol 7:197-208.
13. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787-798.
14. Nuovo GJ (2010) In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. Methods, 10.1016/j.ymeth. 2010.08.009.
15. Valeri N, et al. (2010) Modulation of mismatch repair and genomic stability by miR- 155. Proc Natl Acad Sci USA 107:6982-6987.
16. Li LS, et al. (2009) DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 158: 679-692.
17. Watanabe Y, et al. (2000) Complementation of an hMSH2 defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol Carcinog 29: 37-49.
18. Zhang H, et al. (1999) Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 59:3021-3027.
19. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96: 134-144. (Pubitemid 38195904)
20. Meng F, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658.
21. Lu Z, et al. (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27:4373-4379.
22. Wang P, et al. (2009) microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69:8157-8165.
23. Hatley ME, et al. (2010) Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18:282-293.
24. Medina PP, Nolde M, Slack FJ (2010) OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467:86-90.
25. O'Connell MJ, et al. (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937-3944.
26. Ren Y, et al. (2010) Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21:303-314.
27. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308.
28. Rossi L, Bonmassar E, Faraoni I (2007) Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56:248-253.
29. Bertolini F, et al. (2007) Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68:1455-1461.
30. Samimi G, et al. (2000) Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6:1415-1421.